<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
  <meta http-equiv="Content-Style-Type" content="text/css" />
  <meta name="generator" content="pandoc" />
  <title></title>
  <style type="text/css">code{white-space: pre;}</style>
</head>
<body>
<h3 id="mondo0018887"><a href="http://purl.obolibrary.org/obo/MONDO_0018887">MONDO:0018887</a></h3>
<p><strong>Label:</strong> rare cutaneous lupus erythematosus</p>
<p><strong>Subclasses:</strong> <a href="http://purl.obolibrary.org/obo/MONDO_0019557">MONDO:0019557</a> (Chilblain lupus), <a href="http://purl.obolibrary.org/obo/MONDO_0015574">MONDO:0015574</a> (chronic cutaneous lupus erythematosus),</p>
<p><strong>Corr. equiv. classes:</strong> <a href="http://www.orpha.net/ORDO/Orphanet_163531">Orphanet:163531</a>, <a href="http://purl.obolibrary.org/obo/OMIM_614415">OMIM:614415</a>, <a href="http://www.orpha.net/ORDO/Orphanet_90280">Orphanet:90280</a>, <a href="http://purl.obolibrary.org/obo/OMIM_610448">OMIM:610448</a>,</p>
<p><strong>Class expressions from DL-Learner:</strong></p>
<ul>
<li><a href="http://purl.obolibrary.org/obo/HP_0003493">HP:0003493</a> (Antinuclear antibody positivity) and <a href="http://purl.obolibrary.org/obo/HP_0200042">HP:0200042</a> (Skin ulcer) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001597">HP:0001597</a> (Abnormality of the nail) and <a href="http://purl.obolibrary.org/obo/HP_0003493">HP:0003493</a> (Antinuclear antibody positivity) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0003493">HP:0003493</a> (Antinuclear antibody positivity) and <a href="http://purl.obolibrary.org/obo/HP_0025142">HP:0025142</a> (Constitutional symptom) and <a href="http://purl.obolibrary.org/obo/HP_0200042">HP:0200042</a> (Skin ulcer) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0003493">HP:0003493</a> (Antinuclear antibody positivity) and <a href="http://purl.obolibrary.org/obo/HP_0012823">HP:0012823</a> (Clinical modifier) and <a href="http://purl.obolibrary.org/obo/HP_0200042">HP:0200042</a> (Skin ulcer) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0003493">HP:0003493</a> (Antinuclear antibody positivity) and <a href="http://purl.obolibrary.org/obo/HP_0012531">HP:0012531</a> (Pain) and <a href="http://purl.obolibrary.org/obo/HP_0200042">HP:0200042</a> (Skin ulcer) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0003493">HP:0003493</a> (Antinuclear antibody positivity) and <a href="http://purl.obolibrary.org/obo/HP_0011138">HP:0011138</a> (Abnormality of skin adnexa morphology) and <a href="http://purl.obolibrary.org/obo/HP_0200042">HP:0200042</a> (Skin ulcer) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0003493">HP:0003493</a> (Antinuclear antibody positivity) and <a href="http://purl.obolibrary.org/obo/HP_0003674">HP:0003674</a> (Onset) and <a href="http://purl.obolibrary.org/obo/HP_0200042">HP:0200042</a> (Skin ulcer) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0003493">HP:0003493</a> (Antinuclear antibody positivity) and <a href="http://purl.obolibrary.org/obo/HP_0003621">HP:0003621</a> (Juvenile onset) and <a href="http://purl.obolibrary.org/obo/HP_0200042">HP:0200042</a> (Skin ulcer) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0002829">HP:0002829</a> (Arthralgia) and <a href="http://purl.obolibrary.org/obo/HP_0003493">HP:0003493</a> (Antinuclear antibody positivity) and <a href="http://purl.obolibrary.org/obo/HP_0200042">HP:0200042</a> (Skin ulcer) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001597">HP:0001597</a> (Abnormality of the nail) and <a href="http://purl.obolibrary.org/obo/HP_0003493">HP:0003493</a> (Antinuclear antibody positivity) and <a href="http://purl.obolibrary.org/obo/HP_0200042">HP:0200042</a> (Skin ulcer) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001597">HP:0001597</a> (Abnormality of the nail) and <a href="http://purl.obolibrary.org/obo/HP_0003493">HP:0003493</a> (Antinuclear antibody positivity) and <a href="http://purl.obolibrary.org/obo/HP_0025142">HP:0025142</a> (Constitutional symptom) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001597">HP:0001597</a> (Abnormality of the nail) and <a href="http://purl.obolibrary.org/obo/HP_0003493">HP:0003493</a> (Antinuclear antibody positivity) and <a href="http://purl.obolibrary.org/obo/HP_0012823">HP:0012823</a> (Clinical modifier) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001597">HP:0001597</a> (Abnormality of the nail) and <a href="http://purl.obolibrary.org/obo/HP_0003493">HP:0003493</a> (Antinuclear antibody positivity) and <a href="http://purl.obolibrary.org/obo/HP_0012531">HP:0012531</a> (Pain) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001597">HP:0001597</a> (Abnormality of the nail) and <a href="http://purl.obolibrary.org/obo/HP_0003493">HP:0003493</a> (Antinuclear antibody positivity) and <a href="http://purl.obolibrary.org/obo/HP_0011355">HP:0011355</a> (Localized skin lesion) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001597">HP:0001597</a> (Abnormality of the nail) and <a href="http://purl.obolibrary.org/obo/HP_0003493">HP:0003493</a> (Antinuclear antibody positivity) and <a href="http://purl.obolibrary.org/obo/HP_0011121">HP:0011121</a> (Abnormality of skin morphology) 62.50%</li>
</ul>
</body>
</html>
